$VANI

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 . Regulation FD Disclosure. As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“MergerSu

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. The companies noted no exclusivity. Vivani expects to start a Phase 1 first-in-human trial in mid-2026, comparing with Wegovy, to support a Phase 2 dose-ranging study.

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.

Vivani Medical (Nasdaq: VANI) said it signed a non-exclusive agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Vivani expects to start a Phase 1 first-in-human trial of NPM-139 mid-2026, using Wegovy as an active comparator.

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 7 ex21_1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG CLEARONE INC., CLRO MERGER SUB, INC., CORTIGENT, INC. AND VIVANI MEDICAL, INC. Dated as of July 1, 2026 TABLE OF CONTENTS Page ARTICLE 1 DESCRIPTION OF TRANSACTION 2 1.1 Structure of the Merger

Vivani Medical’s subsidiary Cortigent will merge with ClearOne, with ClearOne renamed Cortigent Holdings and expected to trade on Nasdaq under ticker CRGT. ClearOne will raise $10M–$15M via concurrent financing. Vivani will receive 12.5M shares and is expected to own 59.4%–67.5% of the combined company; former ClearOne holders 12.7%–14.4%.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 7 ex101_1.htm EXHIBIT 10.1 Exhibit 10.1 VIVANI MEDICAL, INC. AMENDED AND RESTATED 2022 OMNIBUS INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amended and Restated Vivani Medical, Inc. 2022 Omnibus Incentive Plan (the “Plan”)